middle.news
Arovella Names Nicole Van Der Weerden Acting CEO Ahead of ALA-101 Trial
8:52am on Thursday 7th of May, 2026 AEST
•
Biotechnology
Read Story
Arovella Names Nicole Van Der Weerden Acting CEO Ahead of ALA-101 Trial
8:52am on Thursday 7th of May, 2026 AEST
Key Points
Dr Nicole Van Der Weerden takes over as acting CEO
Leadership change coincides with upcoming ALA-101 phase I trial
Van Der Weerden’s salary matches predecessor’s at $386,250 plus super
Company to update market on permanent CEO search process
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Arovella Therapeutics (ASX:ALA)
OPEN ARTICLE